Yuna Kim1,2,3, Jae Seung Lee1,2,3, Hye Won Lee1,2,3, Beom Kyung Kim1,2,3, Jun Yong Park1,2,3, Do Young Kim1,2,3, Sang Hoon Ahn1,2,3, Seung Up Kim1,2,3. 1. Department of Internal Medicine, Yonsei University College of Medicine, Seoul 03722, Korea. 2. Yonsei Liver Center, Severance Hospital, Seoul 03722, Korea. 3. Institute of Gastroenterology, Yonsei University College of Medicine, Seoul 03722, Korea.
Abstract
BACKGROUND: Trans-arterial radioembolization (TARE) has shown promising results in treating hepatocellular carcinoma (HCC). We identified independent predictors of radiological complete response (CR) in patients with intrahepatic HCC who were treated with TARE. METHODS: Patients with intrahepatic HCC treated with TARE between 2011 and 2017 were recruited. CR was defined according to the modified Response Evaluation Criteria in Solid Tumors. Cox regression analysis was used to determine independent predictors of CR. RESULTS: The median age of study participants (83 men and 19 women) was 64.3 years. The mean survival after TARE was 55.5 months, and 21 (20.6%) patients died during the study period. Patients who achieved CR (14 patients, 13.7%) had significantly higher serum albumin level (median 4.1 vs. 3.9 g/dL), lower total bilirubin level (median 0.6 vs. 0.7 mg/dL), lower aspartate aminotransferase level (median 30.0 vs. 43.0 IU/L), lower alkaline phosphatase level (median 79.0 vs. 103.0 IU/L), lower alpha-fetoprotein level (median 12.7 vs. 39.9 ng/mL), lower des-gamma-carboxyprothrombin level (median 575.5 vs. 2772.0 mAU/mL), lower model for end-stage liver disease (MELD) score (median 6.0 vs. 7.0), and smaller maximal tumor diameter (median 6.3 vs. 9.0 cm) compared to those who did not achieve CR (all p < 0.005). Multivariate Cox regression analysis showed that lower MELD score (hazard ratio (HR) = 0.436, p = 0.015) and maximal tumor size < 9 cm (HR = 11.180, p = 0.020) were independent predictors of an increased probability of radiological CR after TARE. CONCLUSIONS: Low MELD score and small maximal tumor size were independently associated with an increased probability of CR after TARE in patients with intrahepatic HCC.
BACKGROUND: Trans-arterial radioembolization (TARE) has shown promising results in treating hepatocellular carcinoma (HCC). We identified independent predictors of radiological complete response (CR) in patients with intrahepatic HCC who were treated with TARE. METHODS:Patients with intrahepatic HCC treated with TARE between 2011 and 2017 were recruited. CR was defined according to the modified Response Evaluation Criteria in Solid Tumors. Cox regression analysis was used to determine independent predictors of CR. RESULTS: The median age of study participants (83 men and 19 women) was 64.3 years. The mean survival after TARE was 55.5 months, and 21 (20.6%) patientsdied during the study period. Patients who achieved CR (14 patients, 13.7%) had significantly higher serum albumin level (median 4.1 vs. 3.9 g/dL), lower total bilirubin level (median 0.6 vs. 0.7 mg/dL), lower aspartate aminotransferase level (median 30.0 vs. 43.0 IU/L), lower alkaline phosphatase level (median 79.0 vs. 103.0 IU/L), lower alpha-fetoprotein level (median 12.7 vs. 39.9 ng/mL), lower des-gamma-carboxyprothrombin level (median 575.5 vs. 2772.0 mAU/mL), lower model for end-stage liver disease (MELD) score (median 6.0 vs. 7.0), and smaller maximal tumor diameter (median 6.3 vs. 9.0 cm) compared to those who did not achieve CR (all p < 0.005). Multivariate Cox regression analysis showed that lower MELD score (hazard ratio (HR) = 0.436, p = 0.015) and maximal tumor size < 9 cm (HR = 11.180, p = 0.020) were independent predictors of an increased probability of radiological CR after TARE. CONCLUSIONS: Low MELD score and small maximal tumor size were independently associated with an increased probability of CR after TARE in patients with intrahepatic HCC.
Authors: Georgios C Sotiropoulos; Hauke Lang; Andrea Frilling; Ernesto P Molmenti; Andreas Paul; Silvio Nadalin; Arnold Radtke; Eirini I Brokalaki; Fuat Saner; Philip Hilgard; Guido Gerken; Christoph E Broelsch; Massimo Malagò Journal: Hepatogastroenterology Date: 2006 May-Jun
Authors: Beom Kyung Kim; Seung Up Kim; Myeong-Jin Kim; Kyung Ah Kim; Do Young Kim; Jun Yong Park; Sang Hoon Ahn; Kwang-Hyub Han; Chae Yoon Chon Journal: Clin Cancer Res Date: 2012-12-07 Impact factor: 12.531
Authors: Mi Young Jeon; Hye Won Lee; Beom Kyung Kim; Jun Yong Park; Do Young Kim; Sang Hoon Ahn; Kwang-Hyub Han; Song-Ee Baek; Hye Soo Kim; Seung Up Kim; Mi Suk Park Journal: Liver Int Date: 2018-03-31 Impact factor: 5.828
Authors: Yehyun Park; Beom Kyung Kim; Jun Yong Park; Do Young Kim; Sang Hoon Ahn; Kwang-Hyub Han; Jong Eun Yeon; Kwan Soo Byun; Hye Soo Kim; Ji Hoon Kim; Seung Up Kim Journal: BMC Cancer Date: 2019-04-16 Impact factor: 4.430